Clinical trials: System Sclerosis
Multiple Sclerosis
The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
Participants with multiple sclerosis that are currently treated with glatiramer acetate (GA, Copaxone®) injections and have redness, pain, swelling, itching or a lump at the injection site will be recruited to examine histamine…
- Trial name
- NCT00988988
- Testing
- AGEE cream, 1% Steroid Cream
- Sponsor
- University of Nebraska
Morphea
Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in treating plaque-type morphea.
- Trial name
- NCT00230373
- Testing
- imiquimod 5% cream (Aldara)
- Where
- 3 sites in Canada
- Sponsor
- University of Alberta
Multiple Sclerosis
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
The purpose of this study is to determine what percentage of patients receiving high-dose Cyclophosphamide may experience a halt in the worsening of their disease or experience improvement of their disease and for how long the…
- Trial name
- NCT00296205
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stony Brook University
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
This pilot mixed-method study will evaluate the feasibility, preliminary efficacy, and user experience of a home-based wearable Focal Vibration Therapy (FVT) intervention for improving upper extremity (UEx) function in people…
- Trial name
- NCT07376772
- Testing
- wearable focal vibration therapy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Fatigue, Walking, Difficulty
Neurophysiological Effects of Transcutaneous Electrical Nerve Stimulation in Persons With MS
Transcutaneous Electrical Nerve Stimulation (TENS) is a treatment that could potentially reduce walking problems and fatigue in persons with Multiple Sclerosis.
- Conditions
- Fatigue, Walking, Difficulty, Multiple Sclerosis
- Trial name
- NCT06432686
- Testing
- Transcutaneous Electrical Nerve Stimulation, Movement
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Natalizumab Treatment of Progressive Multiple Sclerosis
The purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis.
- Trial name
- NAPMS (NCT01077466)
- Testing
- Natalizumab
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pediatric Multiple Sclerosis
ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program
The investigators have previously shown that youth with MS are very inactive, and that vigorous physical activity is associated with higher levels of well-being and lower MS disease activity in youth.
- Trial name
- NCT04782466
- Testing
- Physical Activity (PA) Intervention, Waitlist attention-control
- Where
- 3 sites in United States, Canada
- Volunteers
- 56 people
- Sponsor
- The Hospital for Sick Children
ALS (Amyotrophic Lateral Sclerosis)
Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease
Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure.
- Trial name
- NCT07067229
- Testing
- Personalized rTMS, Standard rTMS
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory…
- Trial name
- MSFibroblast (NCT05080270)
- Testing
- Tolerogenic Fibroblasts
- Where
- Mexico
- Volunteers
- 5 people
- Sponsor
- FibroBiologics
Relapsing-remitting Multiple Sclerosis
Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients
the purpose of this study was to evaluate the usefulness of educational kinesiology program to improve cognitive impairement, manual dexterity and bimanual coordination in patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT07002151
- Testing
- educational kinesiology training program intervention for study group, conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Cairo University
Multiple Sclerosis
Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity
Cognitive dysfunction is frequent in patients with multiple sclerosis (MS) and to date, there are no available treatments to improve cognition in this patient population.
- Trial name
- AERCONN (NCT02005237)
- Testing
- Aerobic Exercise
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjögren's Syndrome
- Trial name
- NCT07361094
- Testing
- Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
- Where
- China
- Sponsor
- Beijing Boren Hospital
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- REAL-MS (NCT07899502)
- Testing
- Autologous haematopoietic stem cell transplantation (AHSCT), High-efficacy disease-modifying therapy (HE-DMT)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Autoimmune Diseases
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases.
- Trial name
- LCAR1901 (NCT07121777)
- Testing
- Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Multiple Sclerosis
Lifestyle Intervention for Patients With Multiple Sclerosis
The LIMS study is an observational study that investigates the effectiveness of an online lifestyle program for patients with multiple sclerosis (MS).
- Trial name
- LIMS (NCT05402501)
- Testing
- Lifestyle intervention program "Leef! met MS"
- Where
- Netherlands
- Volunteers
- 900 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsing-remitting Multiple Sclerosis
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
The "SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study" is the follow up study of the "SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS)" (see…
- Trial name
- NCT01111656
- Testing
- Interferon beta-1b group, Interferon beta-1b/Atorvastatin group
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02327845
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Miami
Multiple Sclerosis
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
In this study we wish to test the hypothesis that continuous Gilenya treatment alters immune homeostasis in favor of an anti-inflammatory type II monocyte and macrophage (M2) phenotype in the circulation of patients with…
- Trial name
- NCT02225977
- Testing
- Gilenya
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.